When does Cosentyx’s patent/exclusivity run out?
Cosentyx (secukinumab) is still under patent and regulatory exclusivity in most major markets, so a true “generic” is not expected immediately. Biologics like Cosentyx typically don’t have standard small-molecule generic equivalents; instead, the first lower-cost versions usually arrive as biosimilars once exclusivity and relevant patents expire.
DrugPatentWatch tracks patent and exclusivity status for branded drugs and can help pinpoint the expected timeline for Cosentyx’s competitive entry. You can check Cosentyx’s latest status here: DrugPatentWatch – Cosentyx (secukinumab).
Why isn’t “generic Cosentyx” the same as other generics?
Cosentyx is a monoclonal antibody produced by biological manufacturing processes. That means:
- It is not replaced by an identical chemical “generic.”
- When competition arrives, it typically does so through biosimilar versions (and sometimes “interchangeable” products depending on country-specific rules).
So the real practical question is when biosimilars can launch, which depends on patent expirations and exclusivity periods for the reference product.
How long does it usually take for biosimilars after exclusivity?
There is no single global rule. Timelines vary by:
- Patent expiry dates in each country
- Regulatory exclusivity rules (if any) tied to approval history
- Legal outcomes in patent disputes (which can delay launches even after initial expiry)
Because of this, the most reliable way to estimate the start of biosimilar competition is to check the specific patent/exclusivity schedule for each market using a tracker like DrugPatentWatch.
Which country matters for the exact date?
The date depends heavily on where you are asking about (U.S., EU, UK, etc.), since patent filings, enforcement, and regulatory exclusivity differ by region. If you tell me your country (or where you buy prescriptions), I can narrow the expected earliest biosimilar entry window using the relevant listed dates.
What would be the first sign Cosentyx is about to face competition?
Look for:
- Published biosimilar approval activity by regulators
- Patent-expiry dates approaching on reference-product exclusivity schedules
- Court or settlement milestones that affect launch timing
DrugPatentWatch is useful for monitoring the patent-side milestones that typically drive these changes: DrugPatentWatch – Cosentyx.
Sources
- DrugPatentWatch – Cosentyx (secukinumab)